CpG islands are DNA segments of at least 0.5 kb in size,
|
|
- Cecil Richard
- 6 years ago
- Views:
Transcription
1 Four Molecular Subtypes of Colorectal Cancer and Their Precursor Lesions Gyeong Hoon Kang, MD N Context. In addition to chromosomal instability and microsatellite instability (MSI), a third pathway, epigenetic instability, has been implicated in progression to colorectal carcinogenesis. CpG island methylator phenotype (CIMP) refers to a subset of colorectal cancers (CRCs) that occur through the epigenetic instability pathway and that are characterized by widespread hypermethylation of promoter CpG island loci, resulting in the inactivation of several tumor suppressor genes or tumor-related genes. Colorectal cancers can be classified into 4 molecular subtypes according to their CIMP and MSI statuses: CIMP+/MSI+, CIMP+/MSI2, CIMP2/MSI+, and CIMP2/MSI2. There are differences between Western (United States and European Union) and Eastern (Korea and China) populations in the number of CRCs that are MSI+, and in the number of MSI+ CRCs that are CIMP+. Objective. To review the clinicopathologic and molecular features of the 4 molecular subtypes of CRCs and their precursor lesions, and to emphasize geographic differences in CRCs between Eastern and Western populations. Data Sources. This article is based on the author s own experimental data and a literature review of relevant articles indexed in PubMed (US National Library of Medicine). Conclusion. The 4 molecular subtypes of CRC that are defined by their CIMP and MSI statuses are characterized by their own distinct clinicopathologic and molecular features and precursor lesions. In particular, the clinicopathologic features of MSI+ CRCs differ depending on the CIMP status. Further understanding of the heterogeneity in CRC molecular pathways may help to explain the diverse morphologic features of CRCs. (Arch Pathol Lab Med. 2011;135: ) CpG islands are DNA segments of at least 0.5 kb in size, with a high G:C ratio and CpG content, and are often located in the promoters or 59-exon sequences of genes. 1 Approximately 70% of human genes contain CpG islands in their promoter or 59-exon sequences. 2 More than 90% of CpG islands within promoters have generally been thought to be unmethylated in normal cells, except for those on the inactive X chromosome and those associated with imprinted genes, which are methylated. 3 Hypermethylation of CpG islands within promoters can occur in association with the development of cancer or aging, although the cause is unclear. Hypermethylation of CpG islands leads to the recruitment of methyl-dna binding proteins, and subsequently histone deacetylases. Deacetylation and methylation of the histone tails transforms the chromatin structure of the promoter into a closed structure, leaving it inaccessible to transcription factors and resulting in gene inactivation. 4,5 Hypermethylation of Accepted for publication December 8, From the Department of Pathology and Cancer Research Institute, Brain Korea 2nd Stage, Seoul National University College of Medicine, Seoul, Korea. The author has no relevant financial interest in the products or companies described in this article. Presented at the 9th Spring Seminar of the Korean Pathologists Association of North America; March 18 20, 2010; Washington, DC; in conjunction with the 99th Annual Meeting of the United States and Canadian Academy of Pathology. Reprints: Gyeong Hoon Kang, MD, Department of Pathology, Seoul National University College of Medicine, 28 Yongon-dong, Chongnogu, Seoul , South Korea ( ghkang@snu.ac.kr). promoter CpG islands is thought to act as an alternative mechanism to genetic mutation for the inactivation of tumor suppressor genes in human cancers. Virtually all types of human cancer display hypermethylation of promoter CpG islands, although the prevalence of such hypermethylation varies among tissue types. 6 8 In addition to its potential role in gene inactivation in human cancers, CpG island hypermethylation is now gaining attention as a molecular marker for tumor detection and prediction of clinical outcomes in cancer patients. THREE MOLECULAR PATHWAYS OF COLORECTAL CARCINOGENESIS Since the initial demonstration by Issa et al 9 that inactivation of the estrogen receptor gene in colorectal cancer (CRC) is associated with promoter CpG island hypermethylation, more than 100 genes have been shown to be inactivated by promoter CpG island hypermethylation in CRCs. 10,11 Recent articles 10,12 have demonstrated that the number of genes inactivated by promoter CpG island hypermethylation in CRC is greater than the number of genes that have undergone direct mutation. Accumulating evidence indicates that CRC has substantial genetic heterogeneity, and that CRC actually comprises several different genetic diseases all affecting the same organ. 13 Three mechanisms that increase the diversity of gene expression have been identified in CRC: microsatellite instability (MSI), chromosomal instability (CIN), and CpG island methylator phenotype (CIMP). Microsatellite instability occurs in 6% to 15% of CRCs and is caused by 698 Arch Pathol Lab Med Vol 135, June 2011 Molecular Subtypes of Colorectal Cancer Kang
2 inactivation of DNA mismatch repair genes Chromosomal instability is present in more than 50% of CRCs and is characterized by aneuploidy and frequent loss of heterozygosity, which facilitates the sequential inactivation of APC, DCC/SMAD4, and TP Up to 20% of CRCs demonstrate CIMP, which refers to the widespread hypermethylation of CpG island loci. 21,22 The original studies on CIMP in CRC identified associations with MSI, increased KRAS mutations, decreased TP53 mutations, proximal colon location, and increased age. 23,24 However, inconsistent results have been obtained concerning the association between CIMP and female preponderance or KRAS mutation, depending on the type of CIMP marker panel that was used to define CIMP FOUR MOLECULAR SUBTYPES OF COLORECTAL CANCER Colorectal cancers can be classified by global genomic/ epigenomic aberrations, including CIN, MSI, and CIMP. Classification based on CIN has many problems because the methods/markers and criteria currently used for analysis of CIN are not uniform. Because MSI and CIMP are relatively well defined when compared with CIN, CRCs are usually classified into 4 molecular subtypes on the basis of both CIMP and MSI statuses: CIMP+/MSI2 (5% 10%), CIMP2/MSI2 (75% 80%), CIMP+/MSI+ (10%), and CIMP2/MSI+ (5%). The frequency of each subtype among CRCs (shown in parentheses) is an approximate value obtained from CRCs in an American population, as obtained by Ogino and Goel. 22 We have obtained a largely similar distribution in our study of CRCs in a Korean population. The distributions were as follows: CIMP+/MSI2 (8%), CIMP2/MSI2 (79%), CIMP+/MSI+ (5%), and CIMP2/MSI+ (8%). 29 The ratio of the CIMP+/MSI+ subtype to the CIMP2/MSI+ subtype differs substantially between Western (2:1 ratio) and Korean populations (ratio ranging from 1:1.6 to 1:2.3). 22,30 This discrepancy does not appear to be related to differences in CIMP markers or the methodologies used in the 2 studies, as we (the Korean studies) used 3 different CIMP marker panels (Issa s classic 5-marker panel, 31 Laird s new 5-marker panel, 32 and Ogino s updated 8-marker panel 33 ) and methylation-specific polymerase chain reaction and MethyLight technology. 28,34 PROGNOSTIC IMPLICATIONS OF CIMP Of the 4 molecular subtypes, CIMP+/MSI2 subtype is associated with the worst clinical outcome, a finding that is similar in both Eastern and Western populations. 28,35 37 In our previous study on MSI2 tumors, 28 those that were both CIMP+ and mutated at KRAS/BRAF were associated with the worst clinical outcome, and there were no differences in the clinical outcomes for tumors that were either CIMP+ or mutated at KRAS/BRAF, or neither. This result indicates that the poor clinical outcome observed in patients with CIMP+/MSI2 tumors is related to the presence of coexisting mutations in KRAS or BRAF. Ward et al 35 and Hawkins et al 38 previously demonstrated that increasing levels of tumor methylation were significantly associated with decreased survival for patients with MSI2 tumors, and MSI2 tumors with methylation at 4 or more of the examined 5 CIMP markers were associated with decreased survival, compared with tumors with methylation at 1 to 3 markers or with no methylation. However, our previous study, 34 in which we determined CIMP status by using 2 different 5-marker panels and methylation-specific polymerase chain reaction, demonstrated a different pattern of survival in relation to methylation. MSI2 tumors with methylation at 1 to 3 markers tended to correlate with a worse clinical outcome than MSI2 tumors with no methylation, but a better clinical outcome than MSI2 tumors with methylation at 4 to 5 markers. Highly methylated, MSI2 CRCs were associated with an early rapid drop in postoperative survival, with prolonged survival in the remainder. This biphasic survival pattern raises the possibility that there may be 2 distinct subgroups within the highly methylated, MSI2 CRCs. Exploration of the molecular alterations revealed that the worse-outcome subgroup had a high frequency of KRAS/ BRAF mutations, whereas the better-outcome subgroup did not have KRAS/BRAF mutations. 34 SUPERIORITY OF AN 8-MARKER PANEL IN METHYLIGHT-BASED DIAGNOSIS OF CIMP Three different marker panels are available for Methy- Light-based diagnosis of CIMP, 2 of which contain 5 markers, 31,32 and 1 of which contains 8 markers. 33 It is not yet clear which panel is optimal for CIMP diagnosis. We screened these 3 marker panels against 196 CRC cases and determined CIMP status by using two 5-marker panels and the 8-marker panel. For the 5-marker panels, CRC cases were considered CIMP+ if at least 3 of the markers were methylated; for the 8-marker panel, cutoff values of 5 and 6 markers were each tested for CIMP. Differently defined CIMP+ CRCs were compared by their associations with previously known clinicopathologic features of CIMP+ CRCs. Overall, the 8-marker panel with a cutoff value of 5 outperformed both of the 5-marker panels and the 8-marker panel with a cutoff value of 6, in all comparisons except for an association with old age. These results suggest that the 8-marker panel, with a cutoff value of 5, is best for CIMP diagnosis. 29 The combination of MSI status with CIMP status defined by the 8-marker panel classifies CRCs into 4 molecular subtypes, all of which have their own distinct clinicopathologic and molecular features (Table). DISCREPANCY IN THE PROPORTIONS OF CIMP IN MSI+ CRCS BETWEEN CRCS IN WESTERN AND EASTERN POPULATIONS The prevalence of MSI+ in CRCs in Western populations is approximately 15%, but tends to be lower in Korean populations (7% in 2800 consecutive cases of surgically resected CRC; G.H.K., unpublished data). Notably, the proportion of CIMP+ among MSI+ CRCs is different between the 2 populations. For CRCs in Western populations, approximately two-thirds of sporadic MSI+ CRCs are CIMP+, a result that is consistently obtained regardless of which CIMP panel markers and methylation analysis technologies are used. 15,22,30 In contrast, approximately one-third of MSI+ CRCs are CIMP+ in CRCs in Korean populations, which is a consistent finding regardless of the type of CIMP marker panel or methylation analysis used. 28,34 Environmental or ethnic differences, for example, diet, between Korean and Western populations may account for this discrepancy. Because the prevalence of hereditary nonpolyposis colon cancer is approximately 3% and similar in Eastern (Chinese and Japanese) and Western (European and Arch Pathol Lab Med Vol 135, June 2011 Molecular Subtypes of Colorectal Cancer Kang 699
3 Clinicopathologic and Molecular Features of 4 Molecular Subtypes of Colorectal Cancer Based on Microsatellite Instabilty (MSI) and CpG Island Methylator Phenotype (CIMP) Status a CIMP2/MSI2 (79%) CIMP2/MSI+ (8%) CIMP+/MSI2 (8%) CIMP+/MSI+ (5%) P Value Age, y Female, % Right colon, % ,.001 Differentiation (PD), % ,.001 Higher stage, % ,.001 Metastasis, % LN metastasis, % ,.001 BRAF mutation, % ,.001 KRAS mutation, % Abbreviations: LN, lymph node; PD, poorly differentiated. a A total of 197 cases of colorectal cancer were analyzed. American) patients with CRC, it is plausible that sporadic MSI+ CRCs which are believed to be due to CIMP-related silencing of the mismatch repair gene MLH1 account for the large difference in the proportion of MSI+ CRCs between CRCs in Western and Eastern populations. BRAF MUTATION IS CLOSELY ASSOCIATED WITH CIMP BUT NOT WITH MSI Although some controversy exists regarding the association of CIMP with KRAS mutations, 32,43 mutations in BRAF have been consistently associated with CIMP. Figure 1. Comparison of clinicopathologic and molecular features of CpG island methylator phenotype negative/microsatellite instability positive (CIMP2/MSI+) colorectal cancers (CRCs) (n 5 54) and CIMP+/MSI+ CRCs (n 5 18). The MSI+ CRCs (n 5 72) were retrieved from a consecutive series of 989 patients who underwent curative surgery for CRCs in Seoul National University Hospital, Seoul, Korea, from 2004 to a, The average age of patients with CIMP+/MSI+ CRC was significantly higher than that of patients with CIMP2/MSI+ CRC (Student t test, P,.001). b, The number of tumorinfiltrating CD8 + lymphocytes per high-power field (HPF) was significantly higher in CIMP+/ MSI+ CRCs than in CIMP2/MSI+ CRCs (Student t test, P 5.05). c, A comparison of parameters, such as proximal colon location, polypoid gross morphology, and advanced cancer stage, with marginal differences indicated by an asterisk (*) (P value between.05 and.09) and significant differences indicated by a double asterisk (**) (P,.05) (2-sided Fisher exact test). MLH1 and MSH2, DNA mismatch repair genes. 700 Arch Pathol Lab Med Vol 135, June 2011 Molecular Subtypes of Colorectal Cancer Kang
4 mutations in MSI+ sporadic CRCs. However, recent studies 33,50 provide conflicting evidence on the association between BRAF mutations and MSI. Microsatellite instability status does not correlate with the frequency of BRAF mutations, although the BRAF mutation is positively correlated with CIMP, independent of MSI status. Figure 2. Survival analysis (Kaplan-Meier log-rank test) was performed for 72 microsatellite instability positive (MSI+) colorectal cancers (CRCs). Solid line indicates CpG island methylator phenotype negative (CIMP2)/MSI+ CRCs and dotted line indicates CIMP+/MSI+ CRCs. Although the prevalence rate of CIMP+ CRCs in Eastern populations is only marginally lower than in Western populations, 14,29,32,44 the BRAF mutation rate is lower in CRCs from Korean than Western populations (4.4% versus 9% 17%). 45 A review of the literature 14,25,45 47 indicates that the rates of BRAF mutations are lower in CRCs from Asian populations than US or European populations (4.2% 5.1% versus 9.5% 17%, respectively). In our previous study, % (2 of 19) of MSI+ sporadic CRCs had BRAF mutations, although other studies 48,49 have reported substantially higher occurrences of BRAF CIMP STATUS RELATED DIFFERENCES IN THE CLINICOPATHOLOGIC FEATURES OF MSI+ CRCS MSI+ CRCs have distinct clinicopathologic features compared with MSI2 CRCs: proximal location, marked mucin production, lower tumor stage, larger tumor size, and reduced frequency of nodal or liver metastasis. However, MSI+ tumors are heterogeneous and can be categorized as CIMP+/MSI+ and CIMP2/MSI+. CIMP+/ MSI+ tumors undergo gene inactivation by CIMP, in addition to those inactivated by MSI, which are shared by both subsets of MSI+ CRCs. 51,52 We speculated that the difference in the repertoire of inactivated genes between CIMP+/MSI+ and CIMP2/MSI+ CRCs would be reflected in phenotypic differences of the tumors. To test this hypothesis, we compared the clinicopathologic and molecular features of CIMP+/MSI+ and CIMP /MSI+ tumors and found that features such as old age, poor differentiation, tumor-infiltrating lymphocytes, and the BRAF mutation were significantly more frequent in CIMP+/MSI+ tumors than in CIMP2/MSI+ tumors. Proximal location and advanced tumor stages were also more frequent in CIMP+/MSI+ than in CIMP /MSI+ tumors; however, these features only just reached statistical significance, indicating that they will have to be confirmed in future studies (Figure 1). A polypoid tumor without ulceration (Borrmann type I) was only found in CIMP2/MSI+ tumors. Of note, the molecular difference between these 2 CRC subtypes was associated with critical differences in clinical outcome, since the survival rate after surgery for patients with CIMP+/MSI+ CRC was significantly lower than for patients with CIMP2/MSI+ CRC (Figure 2) (manuscript in preparation). Figure 3. a, Colorectal carcinomas with contiguous adenoma on the margin of the carcinoma (presumed carcinoma ex adenoma). Thirty-nine cases of carcinoma were associated with contiguous conventional adenoma and 3 cases of carcinoma were accompanied by serrated adenoma. b, The methylation status of 8 CpG island methylator phenotype panel markers were analyzed in adenoma and carcinoma components. Arch Pathol Lab Med Vol 135, June 2011 Molecular Subtypes of Colorectal Cancer Kang 701
5 Figure 4. Premalignant lesions of 4 molecular subtypes. Abbreviations: CIMP, CpG island methylator phenotype; CIN, chromosomal instability; CRC, colorectal cancer; HNPCC, hereditary nonpolyposis colon cancer; MSI, microsatellite instability. PRECURSOR LESIONS OF 4 MOLECULAR SUBTYPES Almost all CRCs are thought to develop from preexisting adenomas, and several lines of evidence support this adenoma-to-carcinoma sequence. 53,54 However, CIMP+ carcinomas do not arise from conventional adenomas, such as tubular adenoma, tubulo-villous adenoma, and villous adenoma, but instead develop from sessile or traditional serrated adenomas When we analyzed the methylation status of 8 CIMP markers in CRCs with contiguous, conventional adenoma on the margin of the carcinoma lesion, no difference in the number of methylated genes was noted between the adenomatous and carcinomatous lesions, and the number of methylated genes was low (Figure 3). This result indicates that there is no further increase in CpG island hypermethylation during malignant transformation, and that CIMP+ carcinomas do not arise from conventional adenomas. In our surgical data files, we found 3 cases of CRCs with a contiguous serrated adenoma, which were also analyzed for their methylation status in 8 CIMP markers. The serrated adenoma components and the carcinoma components of all 3 cases were positive for CIMP,withnodifferencesinthenumbersofmethylated markers between the different lesion types (Figure 3). Several researchers have reported a high frequency of BRAF mutations, and a low frequency of KRAS mutations, in serrated polyps (sessile serrated adenoma, traditional serrated adenoma, and hyperplastic polyp), and a low frequency of BRAF mutations and a high frequency of KRAS mutations in conventional adenomas. 59,60 This observation provides further evidence to support the hypothesis that serrated polyps are precursor lesions of CIMP+ CRCs, which have a high frequency of BRAF mutations and a low frequency of KRAS mutations. The precursor lesions of the 4 molecular subtypes are summarized in Figure 4. CIMP+/MSI+ CRCs arise from sessile serrated adenomas admixed with dysplasia, and MSI is thought to be a late event in the multistep progression to carcinogenesis in this molecular subtype. 15,55,56,61 In contrast, MSI is an initiating event and driving force for the progression of the lesion in the CIMP2/MSI+ subtype (hereditary nonpolyposis colon cancer). 15,39 For CIMP2/MSI+ CRCs, the precursor lesion is not serrated polyps but conventional adenomas. 39,62,63 CIMP+/MSI2 tumors arise from either sessile serrated adenomas or traditional serrated adenomas. 57,58,64 In conclusion, CRC is a heterogeneous disease with various pathologic features and clinical behaviors, which are associated with abnormalities in 3 different major molecular pathways: CIN, MSI, and CIMP. The 4 molecular subtypes of CRCs, as defined by combinations of their CIMP and MSI statuses, differ with respect to demographics, clinical features, prognosis, response to therapy, repertories of activated or inactivated genes, and histomorphologic features that can be readily recognized by surgical pathologists. The fact that each molecular subtype of CRCs has its own precursor lesion indicates that the molecular pathways are determined at an early evolutional stage and are already fully established within precursor lesions. The role of surgical pathologists now extends beyond furnishing an accurate tissue diagnosis to providing prognostic information and additional findings relevant to patient management. This approach to the molecular classification of CRCs should accelerate understanding of causation, have an impact on clinical management, and facilitate the development of new ways to prevent and treat CRCs. This study was supported by a grant from the Seoul National University Hospital Research Fund ( ), a grant from the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea ( ), and a Priority Research Centers Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology ( ). References 1. Takai D, Jones PA. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci U S A. 2002;99(6): Saxonov S, Berg P, Brutlag DL. A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. Proc Natl Acad Sci U S A. 2006;103(5): Eckhardt F, Lewin J, Cortese R, et al. DNA methylation profiling of human chromosomes 6, 20 and 22. Nat Genet. 2006;38(12): Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3(6): Laird PW. Cancer epigenetics. Hum Mol Genet. 2005;14(suppl 1):R65 R Park SY, Kim BH, Kim JH, et al. Methylation profiles of CpG island loci in major types of human cancers. J Korean Med Sci. 2007;22(2): Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res. 2001;61(8): Costello JF, Fruhwald MC, Smiraglia DJ, et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet. 2000;24(2): Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet. 1994;7(4): Schuebel KE, Chen W, Cope L, et al. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet. 2007;3(9): Arch Pathol Lab Med Vol 135, June 2011 Molecular Subtypes of Colorectal Cancer Kang
6 11. Keshet I, Schlesinger Y, Farkash S, et al. Evidence for an instructive mechanism of de novo methylation in cancer cells. Nat Genet. 2006;38(2): Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318(5853): Samowitz WS. Genetic and epigenetic changes in colon cancer. Exp Mol Pathol. 2008;85(1): Nosho K, Irahara N, Shima K, et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS ONE. 2008;3(11):e3698. doi: /journal. pone Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138(6): Ward R, Meagher A, Tomlinson I, et al. Microsatellite instability and the clinicopathological features of sporadic colorectal cancer. Gut. 2001;48(6): Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23(3): Samowitz WS, Holden JA, Curtin K, et al. Inverse relationship between microsatellite instability and K-ras and p53 gene alterations in colon cancer. Am J Pathol. 2001;158(4): Samowitz WS, Curtin K, Ma KN, et al. Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev. 2001;10(9): Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology. 2010;138(6): Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology. 2010;138(6): Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. J Mol Diagn. 2008;10(1): Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999;96(15): Toyota M, Ohe-Toyota M, Ahuja N, Issa JP. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Natl Acad Sci U S A. 2000;97(2): Samowitz WS, Albertsen H, Herrick J, et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology. 2005;129(3): Bariol C, Suter C, Cheong K, et al. The relationship between hypomethylation and CpG island methylation in colorectal neoplasia. Am J Pathol. 2003; 162(4): van Rijnsoever M, Grieu F, Elsaleh H, Joseph D, Iacopetta B. Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut. 2002;51(6): Lee S, Cho NY, Choi M, Yoo EJ, Kim JH, Kang GH. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation. Pathol Int. 2008;58(2): Kim JH, Shin SH, Kwon HJ, Cho NY, Kang GH. Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers. Virchows Arch. 2009;455(6): Poynter JN, Siegmund KD, Weisenberger DJ, et al. Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol Biomarkers Prev. 2008;17(11): Chan AO, Issa JP, Morris JS, Hamilton SR, Rashid A. Concordant CpG island methylation in hyperplastic polyposis. Am J Pathol. 2002;160(2): Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38(7): Ogino S, Kawasaki T, Kirkner GJ, Kraft P, Loda M, Fuchs CS. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn. 2007;9(3): Lee S, Cho NY, Yoo EJ, Kim JH, Kang GH. CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels. Arch Pathol Lab Med. 2008;132(10): Ward RL, Cheong K, Ku SL, Meagher A, O Connor T, Hawkins NJ. Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. J Clin Oncol. 2003;21(20): Barault L, Charon-Barra C, Jooste V, et al. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res. 2008;68(20): Shen L, Catalano PJ, Benson AB III, O Dwyer P, Hamilton SR, Issa JP. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin Cancer Res. 2007;13(20): Hawkins N, Norrie M, Cheong K, et al. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology. 2002;122(5): Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348(10): Zhang YZ, Sheng JQ, Li SR, Zhang H. Clinical phenotype and prevalence of hereditary nonpolyposis colorectal cancer syndrome in Chinese population. World J Gastroenterol. 2005;11(10): Fujita S, Moriya Y, Sugihara K, Akasu T, Ushio K. Prognosis of hereditary nonpolyposis colorectal cancer (HNPCC) and the role of Japanese criteria for HNPCC. Jpn J Clin Oncol. 1996;26(5): Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008;26(35): Shen L, Toyota M, Kondo Y, et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci USA. 2007;104(47): Yagi K, Akagi K, Hayashi H, et al. Three DNA methylation epigenotypes in human colorectal cancer. Clin Cancer Res. 2010;16(1): Yuen ST, Davies H, Chan TL, et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res. 2002;62(22): Chang SC, Lin JK, Yang SH, Wang HS, Li AF, Chi CW. Relationship between genetic alterations and prognosis in sporadic colorectal cancer. Int J Cancer. 2006;118(7): Fransen K, Klintenas M, Osterstrom A, Dimberg J, Monstein HJ, Soderkvist P. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis. 2004;25(4): Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 2005;65(14): Nagasaka T, Sasamoto H, Notohara K, et al. Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol. 2004;22(22): Cheng YW, Pincas H, Bacolod MD, et al. CpG island methylator phenotype associates with low-degree chromosomal abnormalities in colorectal cancer. Clin Cancer Res. 2008;14(19): Poulogiannis G, Frayling IM, Arends MJ. DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome. Histopathology. 2010;56(2): Watanabe T, Kobunai T, Toda E, et al. Distal colorectal cancers with microsatellite instability (MSI) display distinct gene expression profiles that are different from proximal MSI cancers. Cancer Res. 2006;66(20): Day DW, Morson BC. The adenoma-carcinoma sequence. Major Probl Pathol. 1978;10: Jackman RJ, Mayo CW. The adenoma-carcinoma sequence in cancer of the colon. Surg Gynecol Obstet. 1951;93(3): Goldstein NS, Bhanot P, Odish E, Hunter S. Hyperplastic-like colon polyps that preceded microsatellite-unstable adenocarcinomas. Am J Clin Pathol. 2003; 119(6): Hawkins NJ, Ward RL. Sporadic colorectal cancers with microsatellite instability and their possible origin in hyperplastic polyps and serrated adenomas. J Natl Cancer Inst. 2001;93(17): Noffsinger AE. Serrated polyps and colorectal cancer: new pathway to malignancy. Annu Rev Pathol. 2009;4: Vakiani E, Yantiss RK. Pathologic features and biologic importance of colorectal serrated polyps. Adv Anat Pathol. 2009;16(2): Minoo P, Moyer MP, Jass JR. Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis. J Pathol. 2007;212(2): Jass JR, Baker K, Zlobec I, et al. Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a fusion pathway to colorectal cancer. Histopathology. 2006;49(2): Samowitz WS, Slattery ML. Microsatellite instability in colorectal adenomas. Gastroenterology. 1997;112(5): Pino MS, Mino-Kenudson M, Wildemore BM, et al. Deficient DNA mismatch repair is common in Lynch syndrome-associated colorectal adenomas. J Mol Diagn. 2009;11(3): Jass JR, Stewart SM. Evolution of hereditary non-polyposis colorectal cancer. Gut. 1992;33(6): Messick CA, Church J, Casey G, Kalady MF. Identification of the methylator (serrated) colorectal cancer phenotype through precursor serrated polyps. Dis Colon Rectum. 2009;52(9): Arch Pathol Lab Med Vol 135, June 2011 Molecular Subtypes of Colorectal Cancer Kang 703
The Role of the CpG Island Methylator Phenotype on Survival Outcome in Colon Cancer
Gut and Liver, Vol. 9, No. 2, March 215, pp. 22-27 ORiginal Article The Role of the CpG Island Methylator Phenotype on Survival Outcome in Colon Cancer Ki Joo Kang*, Byung-Hoon Min, Kyung Ju Ryu, Kyoung-Mee
More informationSerrated Polyps and a Classification of Colorectal Cancer
Serrated Polyps and a Classification of Colorectal Cancer Ian Chandler June 2011 Structure Serrated polyps and cancer Molecular biology The Jass classification The familiar but oversimplified Vogelsteingram
More informationClinical and Pathological Significance of Epigenomic Changes in Colorectal Cancer
Clinical and Pathological Significance of Epigenomic Changes in Colorectal Cancer Shuji Ogino, M.D., Ph.D. Associate Professor of Pathology Harvard Medical School Brigham and Women s Hospital Dana-Farber
More informationDevelopment of Carcinoma Pathways
The Construction of Genetic Pathway to Colorectal Cancer Moriah Wright, MD Clinical Fellow in Colorectal Surgery Creighton University School of Medicine Management of Colon and Diseases February 23, 2019
More informationGeneral Session 7: Controversies in Screening and Surveillance in Colorectal Cancer
General Session 7: Controversies in Screening and Surveillance in Colorectal Cancer Complexities of Pathological Assessment: Serrated Polyps/Adenomas Carolyn Compton, MD, PhD Professor of Life Sciences,
More informationCpG Island Methylator Phenotype-Low (CIMP-Low) in Colorectal Cancer: Possible Associations with Male Sex and KRAS Mutations
Journal of Molecular Diagnostics, Vol. 8, No. 5, November 2006 Copyright American Society for Investigative Pathology and the Association for Molecular Pathology DOI: 10.2353/jmoldx.2006.060082 CpG Island
More informationT ranscriptional inactivation by cytosine methylation at
1000 GASTROINTESTINAL CANCER CpG island methylator phenotype () of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies S Ogino, M Cantor, T Kawasaki,
More informationSynchronous and Subsequent Lesions of Serrated Adenomas and Tubular Adenomas of the Colorectum
Tsumura T, et al 1 Synchronous and Subsequent Lesions of Serrated Adenomas and Tubular Adenomas of the Colorectum T. Tsumura a T. Hiyama d S. Tanaka b M. Yoshihara d K. Arihiro c K. Chayama a Departments
More informationEvaluation of Markers for CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer by a Large Population-Based Sample
JMD CME Program Journal of Molecular Diagnostics, Vol. 9, No. 3, July 2007 Copyright American Society for Investigative Pathology and the Association for Molecular Pathology DOI: 10.2353/jmoldx.2007.060170
More informationSerrated Polyps, Part 2: Their Mechanisms and Management Ryan C. Romano, DO
Polyps, Part 2: Their Mechanisms and Management Ryan C. Romano, DO In the prelude to this article ( Polyps Part I: Their Confusing History) we discussed the evolution of colorectal serrated polyp classification,
More informationMutations in Both KRAS and BRAF May Contribute to the Methylator Phenotype in Colon Cancer
GASTROENTEROLOGY 2008;34:950 960 Mutations in Both KRAS and BRAF May Contribute to the Methylator Phenotype in Colon Cancer TAKESHI NAGASAKA,* MINORU KOI,* MATTHIAS KLOOR, JOHANNES GEBERT, ALEX VILKIN,*
More informationCpG Island Methylator Phenotype in Primary Gastric Carcinoma
Showa Univ J Med Sci 25 2, 127 132, June 2013 Original CpG Island Methylator Phenotype in Primary Gastric Carcinoma Masayuki TOJO 1, Kazuo KONISHI 1, Yuichiro YANO 1, Atsushi KATAGIRI 1, Hisako NOZAWA
More informationEpigenetic profiling of synchronous colorectal neoplasias by quantitative DNA methylation analysis
& 2006 USCAP, Inc All rights reserved 0893-3952/06 $30.00 www.modernpathology.org Epigenetic profiling of synchronous colorectal neoplasias by quantitative DNA methylation analysis Shuji Ogino 1,2,3, Mohan
More informationNIH Public Access Author Manuscript Gastroenterology. Author manuscript; available in PMC 2009 June 1.
NIH Public Access Author Manuscript Published in final edited form as: Gastroenterology. 2008 June ; 134(7): 1950 1960.e1. doi:10.1053/j.gastro.2008.02.094. Mutations in both KRAS and BRAF may contribute
More informationColon Cancer and Hereditary Cancer Syndromes
Colon Cancer and Hereditary Cancer Syndromes Gisela Keller Institute of Pathology Technische Universität München gisela.keller@lrz.tum.de Colon Cancer and Hereditary Cancer Syndromes epidemiology models
More informationMolecular Subtypes of Colorectal Cancer and Their Clinicopathologic Features, With an Emphasis on the Serrated Neoplasia Pathway
Molecular Subtypes of Colorectal Cancer and Their Clinicopathologic Features, With an Emphasis on the Serrated Neoplasia Pathway Jeong Mo Bae, MD; Jung Ho Kim, MD, PhD; Gyeong Hoon Kang, MD, PhD Context.
More informationHyperplastische Polyps Innocent bystanders?
Hyperplastische Polyps Innocent bystanders?? K. Geboes P th l i h O tl dk d Pathologische Ontleedkunde, KULeuven Content Historical Classification Relation Hyperplastic polyps carcinoma The concept cept
More informationClinicopathologic Characteristics of Left-Sided Colon Cancers with High Microsatellite Instability
The Korean Journal of Pathology 29; 43: 428-34 DOI: 1.4132/KoreanJPathol.29.43.5.428 Clinicopathologic Characteristics of Left-Sided Colon Cancers with High Microsatellite Instability Sang Kyum Kim Junjeong
More informationSerrated Lesions in the Bowel Cancer Screening Programme
Serrated Lesions in the Bowel Cancer Screening Programme Mark Arends Cambridge & Edinburgh Serrated Lesions of Large Bowel 1. Hyperplastic polyp 2. Serrated adenoma 3. Mixed polyp 4. Sessile serrated lesion
More informationThe silence of the genes: clinical applications of (colorectal) cancer epigenetics
The silence of the genes: clinical applications of (colorectal) cancer epigenetics Manon van Engeland, PhD Dept. of Pathology GROW - School for Oncology & Developmental Biology Maastricht University Medical
More informationBeyond the APC era Alternative pathways to CRC. Jeremy R Jass McGill University
Beyond the APC era Alternative pathways to CRC Jeremy R Jass McGill University Outline Limitations of APC model KRAS and serrated polyps CRC and CpG island methylation Serrated pathway to CRC Fusion pathways
More informationColorectal cancer Chapelle, J Clin Oncol, 2010
Colorectal cancer Chapelle, J Clin Oncol, 2010 Early-Stage Colorectal cancer: Microsatellite instability, multigene assay & emerging molecular strategy Asit Paul, MD, PhD 11/24/15 Mr. X: A 50 yo asymptomatic
More informationBRAF Testing In The Elderly: Same As in Younger Patients?
EGFR, K-RAS, K BRAF Testing In The Elderly: Same As in Younger Patients? Nadine Jackson McCleary MD MPH Gastrointestinal Oncology Dana-Farber/Harvard Cancer Care Boston, MA, USA Outline Colorectal cancer
More informationSerrated Colorectal Polyps New Challenges to Old Dogma. Kenneth Batts, M.D. Abbott Northwestern Hospital Minneapolis, MN
Serrated Colorectal Polyps New Challenges to Old Dogma Kenneth Batts, M.D. Abbott Northwestern Hospital Minneapolis, MN A Sneak Preview.... This was in the good old days: Adenomas HPPs Mixed Polyps A Sneak
More informationOriginal Article Frequent CpG island methylation: a risk factor in the progression of traditional serrated adenoma of the colorectum
Int J Clin Exp Pathol 2017;10(9):9666-9674 www.ijcep.com /ISSN:1936-2625/IJCEP0045970 Original Article Frequent CpG island methylation: a risk factor in the progression of traditional serrated adenoma
More informationColorectal carcinoma (CRC) was traditionally thought of
Testing for Defective DNA Mismatch Repair in Colorectal Carcinoma A Practical Guide Lawrence J. Burgart, MD Context. Significant bench and clinical data have been generated during the last decade regarding
More informationColorectal adenocarcinoma leading cancer in developed countries In US, annual deaths due to colorectal adenocarcinoma 57,000.
Colonic Neoplasia Remotti Colorectal adenocarcinoma leading cancer in developed countries In US, annual incidence of colorectal adenocarcinoma 150,000. In US, annual deaths due to colorectal adenocarcinoma
More informationGeneral Surgery Grand Grounds
General Surgery Grand Grounds University of Colorado Health Sciences Center Case Presentation December 24, 2009 Adam Lackey, PGY-5 J.L. - 2111609 27 YO female with chief complaint of abdominal pain. PMHx:
More informationThe molecular genetics of colorectal cancer
1 Department of Gastroenterology, North Middlesex University Hospital, London, UK 2 Institute of Molecular Genetics, Cardiff University 3 Department of Gastroenterology, Queen s Hospital Romford, London,
More informationMicrosatellite instability and other molecular markers: how useful are they?
Microsatellite instability and other molecular markers: how useful are they? Pr Frédéric Bibeau, MD, PhD Head, Pathology department CHU de Caen, Normandy University, France ESMO preceptorship, Barcelona,
More informationAnatomic Molecular Pathology: An Emerging Field
Anatomic Molecular Pathology: An Emerging Field Antonia R. Sepulveda M.D., Ph.D. University of Pennsylvania asepu@mail.med.upenn.edu 2008 ASIP Annual Meeting Anatomic pathology (U.S.) is a medical specialty
More informationAberrant CpG Island Hypermethylation in Pediatric Gastric Mucosa in Association With Helicobacter pylori Infection
Aberrant CpG Island Hypermethylation in Pediatric Gastric Mucosa in Association With Helicobacter pylori Infection So-Hyun Shin, MSc; Seog-Yun Park, MD; Jae-Sung Ko, MD; Nayoung Kim, MD; Gyeong Hoon Kang,
More informationM. Azzam Kayasseh,Dubai,UAE
Thanks A Lot Prof. Linda + Prof. Ernst #drkayasseh_crc_rsm #WEO_CRCSC #UEGW17 @dubaiendoscopyforum @drkayasseh.care.to.cure Twenty World Areas Age-Standardized CRC Incidence Rates by Sex GLOBOCAN 2008
More informationDepartment of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
& 2008 USCAP, Inc All rights reserved 0893-3952/08 $30.00 www.modernpathology.org CpG island methylator phenotype-low (CIMP-low) colorectal cancer shows not only few methylated CIMP-high-specific CpG islands,
More informationSessile Serrated Polyps
Årsmøtet i Den norske Patologforening 2014 Sessile Serrated Polyps Tor J. Eide Oslo Universitetssykehus The term serrated include a group of lesions with a sawtoothlike appearance of the crypts and the
More informationCOLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer
COLORECTAL PATHWAY GROUP, MANCHESTER CANCER Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer March 2017 1 Background Mismatch repair (MMR) deficiency is seen in approximately
More informationB Base excision repair, in MUTYH-associated polyposis and colorectal cancer, BRAF testing, for hereditary colorectal cancer, 696
Index Note: Page numbers of article titles are in boldface type. A Adenomatous polyposis, familial. See Familial adenomatous polyposis. Anal anastomosis, ileal-pouch, proctocolectomy with, in FAP, 591
More informationLarge Colorectal Adenomas An Approach to Pathologic Evaluation
Anatomic Pathology / LARGE COLORECTAL ADENOMAS AND PATHOLOGIC EVALUATION Large Colorectal Adenomas An Approach to Pathologic Evaluation Elizabeth D. Euscher, MD, 1 Theodore H. Niemann, MD, 1 Joel G. Lucas,
More informationHigh risk stage II colon cancer
High risk stage II colon cancer Joel Gingerich, MD, FRCPC Assistant Professor Medical Oncologist University of Manitoba CancerCare Manitoba Disclaimer No conflict of interests 16 October 2010 Overview
More informationPERSPECTIVES. CpG island methylator phenotype in cancer. Jean-Pierre Issa
OPINION CpG island methylator phenotype in cancer Jean-Pierre Issa Abstract DNA hypermethylation in CpG-rich promoters is now recognized as a common feature of human neoplasia. However, the pathophysiology
More informationCOLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer
COLORECTAL PATHWAY GROUP, MANCHESTER CANCER Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer January 2015 1 Background Mismatch repair (MMR) deficiency is seen in approximately
More informationResearch Article The CIMP Phenotype in BRAF Mutant Serrated Polyps from a Prospective Colonoscopy Patient Cohort
Gastroenterology Research and Practice, Article ID 374926, 1 pages http://dx.doi.org/1.1155/214/374926 Research Article The CIMP Phenotype in BRAF Mutant Serrated Polyps from a Prospective Colonoscopy
More informationGENETICS OF COLORECTAL CANCER: HEREDITARY ASPECTS By. Magnitude of the Problem. Magnitude of the Problem. Cardinal Features of Lynch Syndrome
GENETICS OF COLORECTAL CANCER: HEREDITARY ASPECTS By HENRY T. LYNCH, M.D. 1 Could this be hereditary Colon Cancer 4 Creighton University School of Medicine Omaha, Nebraska Magnitude of the Problem Annual
More informationEPIGENETIC SILENCING OF MLH1 AND p16 INK AND THEIR RELATION TO CERTAIN CLINICO- PATHOLOGICAL FEATURES IN PATIENTS WITH COLORECTAL CANCER
Journal of IMAB - Annual Proceeding (Scientific Papers) 2007, vol. 13, book 1 EPIGENETIC SILENCING OF MLH1 AND p16 INK AND THEIR RELATION TO CERTAIN CLINICO- PATHOLOGICAL FEATURES IN PATIENTS WITH COLORECTAL
More informationA WHO update on Serrated Polyps
A WHO update on Serrated Polyps Arzu Ensari, MD, PhD Department of Pathology Ankara University Medical School Am J Gastroenterol. 2010 Nov 2. [Epub ahead of The Clinical Significance of Serrated Polyps.
More informationA Review from the Genetic Counselor s Perspective
: A Review from the Genetic Counselor s Perspective Erin Sutcliffe, MS, CGC Certified Genetic Counselor Cancer Risk Evaluation Program INTRODUCTION Errors in base pair matching that occur during DNA replication,
More informationColorectal Carcinoma Reporting in 2009
Colorectal Carcinoma Reporting in 2009 Overview Colorectal carcinoma- new and confusing AJCC TNM issues Wendy L. Frankel, M.D. Vice-Chair and Director of AP Department of Pathology The Ohio State University
More informationUpdate on Colonic Serrated (and Conventional) Adenomatous Polyps
Update on Colonic Serrated (and Conventional) Adenomatous Polyps Maui, HI 2018 Robert D. Odze, MD, FRCPC Chief, Division of GI Pathology Professor of Pathology Brigham and Women s Hospital Harvard Medical
More informationColon Cancer Update Christie J. Hilton, DO
POMA Winter Conference Christie Hilton DO Medical Oncology January 2018 None Colon Cancer Numbers Screening (brief update) Practice changing updates in colon cancer MSI Testing Immunotherapy in Colon Cancer
More informationMeasure Description. Denominator Statement
CMS ID/CMS QCDR ID: CAP 18 Title: Mismatch Repair (MMR) or Microsatellite Instability (MSI) Biomarker Testing to Inform Clinical Management and Treatment Decisions in Patients with Primary or Metastatic
More informationColonic Polyp. Najmeh Aletaha. MD
Colonic Polyp Najmeh Aletaha. MD 1 Polyps & classification 2 Colorectal cancer risk factors 3 Pathogenesis 4 Surveillance polyp of the colon refers to a protuberance into the lumen above the surrounding
More informationGuidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer
Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer Start date: May 2015 Review date: April 2018 1 Background Mismatch repair (MMR) deficiency is seen in approximately 15%
More informationHisto-prognostic factors what histopathology has to offer for clinical decision making
Histo-prognostic factors what histopathology has to offer for clinical decision making Daniela E. Aust Institute for Pathology, University Hospital Dresden, Germany Center for Molecular Tumor Diagnostics
More informationCAP Laboratory Improvement Programs. Summary of Microsatellite Instability Test Results From Laboratories Participating in Proficiency Surveys
CAP Laboratory Improvement Programs Summary of Microsatellite Instability Test Results From Laboratories Participating in Proficiency Surveys Proficiency Survey Results From 2005 to 2012 Theresa A. Boyle,
More informationMolecular biology of colorectal cancer
Molecular biology of colorectal cancer Phil Quirke Yorkshire Cancer Research Centenary Professor of Pathology University of Leeds, UK Rapid pace of molecular change Sequencing changes 2012 1,000 genomes
More informationCarcinogenesis in IBD
Oxford Inflammatory Bowel Disease MasterClass Carcinogenesis in IBD Dr Simon Leedham, Oxford, UK Oxford Inflammatory Bowel Disease MasterClass Carcinogenesis in Inflammatory Bowel Disease Dr Simon Leedham
More informationArzu Ensari, MD, PhD Department of Pathology Ankara University Medical School
Precursors of Colorectal Carcinoma Arzu Ensari, MD, PhD Department of Pathology Ankara University Medical School Hyperplastic polyp Adenomatous polyp Colorectal carcinoma IBD-associated (1-2%) Sporadic
More informationPathology perspective of colonic polyposis syndromes
Pathology perspective of colonic polyposis syndromes When are too many polyps too many? David Schaeffer Head and Consultant Pathologist, Department of Pathology and Laboratory Medicine, Vancouver General
More informationGenetic testing all you need to know
Genetic testing all you need to know Sue Clark Consultant Colorectal Surgeon, St Mark s Hospital, London, UK. Colorectal cancer Familial 33% Polyposis syndromes
More informationEarly (and not so early) colorectal cancer: The pathologist s point of view
Early (and not so early) colorectal cancer: The pathologist s point of view Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany Disclosure slide I Member of advisory board for
More informationDisclosure slide I Member of advisory board for AMGEN, ROCHE, BOEHRINGER I Speaker honoraria from FALK Pharma, Pfizer, Lilly and ROCHE I Third party f
Early (and not so early) colorectal cancer: The pathologist s point of view Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany Disclosure slide I Member of advisory board for
More informationMismatch repair status, inflammation and outcome in patients with primary operable colorectal cancer
Mismatch repair status, inflammation and outcome in patients with primary operable colorectal cancer Park JH, Powell AG, Roxburgh CSD, Richards CH, Horgan PG, McMillan DC, Edwards J James Park Clinical
More informationResearch Article CpG Island Methylator Phenotype and Prognosis of Colorectal Cancer in Northeast China
BioMed Research International, Article ID 236361, 9 pages http://dx.doi.org/10.1155/2014/236361 Research Article CpG Island Methylator Phenotype and Prognosis of Colorectal Cancer in Northeast China Xia
More informationThe CpG Island Methylator Phenotype and Chromosomal Instability Are Inversely Correlated in Sporadic Colorectal Cancer
GASTROENTEROLOGY 2007;132:127 138 The CpG Island Methylator Phenotype and Chromosomal Instability Are Inversely Correlated in Sporadic Colorectal Cancer AJAY GOEL,* TAKESHI NAGASAKA,* CHRISTIAN N. ARNOLD,
More informationPublished OnlineFirst October 14, 2009; DOI: / CCR
Published OnlineFirst October 14, 2009; DOI: 10.1158/1078-0432.CCR-09-1438 Imaging, Diagnosis, Prognosis Lymphocytic Reaction to Colorectal Cancer Is Associated with Longer Survival, Independent of Lymph
More informationIncidence and Multiplicities of Adenomatous Polyps in TNM Stage I Colorectal Cancer in Korea
Original Article Journal of the Korean Society of J Korean Soc Coloproctol 2012;28(4):213-218 http://dx.doi.org/10.3393/jksc.2012.28.4.213 pissn 2093-7822 eissn 2093-7830 Incidence and Multiplicities of
More informationColorectal cancer molecular biology moves into clinical practice
1 Department of Laboratory Medicine, University of Washington, Washington, USA 2 Clinical Research Division, Fred Hutchison Cancer Research Center, Washington, USA 3 Department of Medicine, University
More informationMolecular markers in colorectal cancer. Wolfram Jochum
Molecular markers in colorectal cancer Wolfram Jochum Biomarkers in cancer Patient characteristics Tumor tissue Normal cells Serum Body fluids Predisposition Diagnostic marker Specific diagnosis Prognostic
More informationColonic polyps and colon cancer. Andrew Macpherson Director of Gastroentology University of Bern
Colonic polyps and colon cancer Andrew Macpherson Director of Gastroentology University of Bern Improtance of the problem of colon cancers - Epidemiology Lifetime risk 5% Incidence/10 5 /annum (US Detroit
More informationPolicy Specific Section: March 1, 2005 January 30, 2015
Medical Policy Fecal DNA Analysis for Colorectal Cancer Screening Type: Investigational / Experimental Policy Specific Section: Laboratory/Pathology Original Policy Date: Effective Date: March 1, 2005
More informationArthur Purdy Stout Society of Surgical Pathologists Companion Meeting. Microsatellite Instability and Serrated Adenomas in Common Practice
Arthur Purdy Stout Society of Surgical Pathologists Companion Meeting Microsatellite Instability and Serrated Adenomas in Common Practice United States and Canadian Academy of Pathology Annual Meeting
More informationMolecular Diagnosis for Colorectal Cancer Patients
Molecular Diagnosis for Colorectal Cancer Patients Antonia R. Sepulveda MD, PhD, FCAP October, 20, 2010 www.cap.org Welcome to the PHC Webinar Series This talk on The Molecular Diagnosis for Colorectal
More informationColorectal Neoplasia. Dr. Smita Devani MBChB, MRCP. Consultant Physician and Gastroenterologist Aga Khan University Hospital, Nairobi
Colorectal Neoplasia Dr. Smita Devani MBChB, MRCP Consultant Physician and Gastroenterologist Aga Khan University Hospital, Nairobi Case History BT, 69yr male Caucasian History of rectal bleeding No change
More informationClinicopathologic Factors Identify Sporadic Mismatch Repair Defective Colon Cancers
Anatomic Pathology / MORPHOLOGY IN MMR-DEFECTIVE COLON CANCER Clinicopathologic Factors Identify Sporadic Mismatch Repair Defective Colon Cancers Britta Halvarsson, MD, PhD, 1 Harald Anderson, PhD, 2 Katarina
More informationWHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER?
CANCER STAGING TNM and prognosis in CRC WHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER? Alessandro Lugli, MD Institute of Pathology University of Bern Switzerland Maastricht, June 19
More informationMolecular subtyping: how useful is it?
Molecular subtyping: how useful is it? Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany Center for Molecular Tumor Diagnostics at the NCT-Partner Site Dresden CMTD Disclosure
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationDifference in the recurrence rate between right- and left-sided colon cancer: a 17-year experience at a single institution
Surg Today (2014) 44:1685 1691 DOI 10.1007/s00595-013-0748-5 ORIGINAL ARTICLE Difference in the recurrence rate between right- and left-sided colon cancer: a 17-year experience at a single institution
More informationWhat Pathology can tell us in the approach of localized colorectal cancer
What Pathology can tell us in the approach of localized colorectal cancer A/Prof Tony Lim Kiat Hon Department of Anatomical Pathology Singapore General Hospital ESMO 2017 Singapore Nov 1 2 Do we still
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal surgery prior as factor in laparoscopic colorectal surgery, 554 555 Abscess(es) CRC presenting as, 539 540 Adenocarcinoma of
More informationFamilial and Hereditary Colon Cancer
Familial and Hereditary Colon Cancer Aasma Shaukat, MD, MPH, FACG, FASGE, FACP GI Section Chief, Minneapolis VAMC Associate Professor, Division of Gastroenterology, Department of Medicine, University of
More informationColorectal Cancer Expression of Peroxisome Proliferator-Activated Receptor (PPARG, PPARgamma) Is Associated With Good Prognosis
GASTROENTEROLOGY 2009;136:1242 1250 Colorectal Cancer Expression of Peroxisome Proliferator-Activated Receptor (PPARG, PPARgamma) Is Associated With Good Prognosis SHUJI OGINO,*,, KAORI SHIMA,* YOSHIFUMI
More informationLa genetica del carcinoma colo-rettale
La genetica del carcinoma colo-rettale Ivana Cataldo Ospedale Ca Foncello, Treviso ARC-NET Centro di Ricerca Applicata sul Cancro AOUI, Verona OUTLINE What s new in colorectal cancer? Pathological Markers
More informationThe Natural History of Right-Sided Lesions
The Natural History of Right-Sided Lesions Jasper L.A. Vleugels Dept of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, the Netherlands. None Disclosures Agenda Is there evidence that
More informationContent. Diagnostic approach and clinical management of Lynch Syndrome: guidelines. Terminology. Identification of Lynch Syndrome
of Lynch Syndrome: guidelines 17/03/2009 Content Terminology Lynch Syndrome Presumed Lynch Syndrome Familial Colorectal Cancer Identification of Lynch Syndrome Amsterdam II criteria Revised Bethesda Guidelines
More informationASSESSMENT OF MLH1 PROMOTER METHYLATION IN ENDOMETRIAL CANCER USING PYROSEQUENCING TECHNOLOGY OBJECTIVES
ASSESSMENT OF MLH1 PROMOTER METHYLATION IN ENDOMETRIAL CANCER USING PYROSEQUENCING TECHNOLOGY Authors: Duilio Della Libera, Alessandra D Urso, Federica Modesti, Georgeta Florea, Marta Gobbato Hospital:
More informationColorectal cancer (CRC) is a common disease that
GASTROENTEROLOGY 2011;140:1174 1181 5-Fluorouracil Adjuvant Chemotherapy Does Not Increase Survival in Patients With CpG Island Methylator Phenotype Colorectal Cancer RODRIGO JOVER,*, THUY PHUONG NGUYEN,
More informationHyperplastic polyps in hereditary nonpolyposis colorectal cancer
4 Hyperplastic polyps in hereditary nonpolyposis colorectal cancer F E M Rijcken 1, T van der Sluis 2, H Hollema 2, J H Kleibeuker 1 Department of Gastroenterology 1 and Pathology 2, University Medical
More informationDouglas K. Rex, MD Indiana University Hospital Indianapolis, IN
Serrated Adenomas: What do they mean and what to do about them? Douglas K. Rex, MD Indiana University Hospital Indianapolis, IN Colorectal Cancer Molecular Basis Pathway Frequency Genes MSI Precursor Speed
More informationMultiplicity of Advanced T Category Tumors Is a Risk Factor for Survival in Patients with Colorectal Carcinoma
Journal of Pathology and Translational Medicine 2018; 52: 386-395 ORIGINAL ARTICLE Multiplicity of Advanced T Category Tumors Is a Risk Factor for Survival in Patients with Colorectal Carcinoma Hye Eun
More informationFamilial and Hereditary Colon Cancer
Familial and Hereditary Colon Cancer Aasma Shaukat, MD, MPH, FACG, FASGE, FACP GI Section Chief, Minneapolis VAMC Associate Professor, Division of Gastroenterology, Department of Medicine, University of
More informationcolorectal cancer Colorectal cancer hereditary sporadic Familial 1/12/2018
colorectal cancer Adenocarcinoma of the colon and rectum is the third most common site of new cancer cases and deaths in men (following prostate and lung or bronchus cancer) and women (following breast
More informationAlberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines
Alberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines June 2013 ACRCSP Post Polypectomy Surveillance Guidelines - 2 TABLE OF CONTENTS Background... 3 Terms, Definitions
More informationResource impact report: Molecular testing strategies for Lynch syndrome in people with colorectal cancer (DG27)
Putting NICE guidance into practice Resource impact report: Molecular testing strategies for Lynch syndrome in people with colorectal cancer (DG27) Published: February 2017 Summary Molecular testing strategies
More informationWEO CRC SC Meeting. Barcelona, Spain October 23, 2015
WEO CRC SC Meeting Barcelona, Spain October 23, 2015 Identification of serrated polyposis syndrome in the context of population-based CRC screening programs Evelien Dekker Academic Medical Center Amsterdam,
More informationMeasure Specifications Measure Description
CMS ID/CMS QCDR ID: CAP 15 Title: BRAF Biomarker Testing to Inform Clinical Management and Treatment Decisions in Patients with Metastatic Colorectal Adenocarcinoma Specifications Description Denominator
More informationPathology of serrated colorectal lesions
Correspondence to Dr Adrian C Bateman, Department of Cellular Pathology, University Hospital Southampton NHS Foundation Trust, MP002, Level E, South Block, Southampton General Hospital, Tremona Road, Southampton
More informationGastroenterology, Hepatology & Digestive Disorders
Research Article Gastroenterology, Hepatology & Digestive Disorders Investigating the Prevalence and Progression of Serrated Polyps Tampa VA Experience Shreya Narayanan MD 1*, Brijesh B. Patel MD 2, David
More informationThe association between CDH1 promoter methylation and patients with ovarian cancer: a systematic meta-analysis
Wang et al. Journal of Ovarian Research (2016) 9:23 DOI 10.1186/s13048-016-0231-1 RESEARCH The association between CDH1 promoter methylation and patients with ovarian cancer: a systematic meta-analysis
More informationAgenda 8:30 AM. Jennifer L. Hunt
Agenda Topic Introduction Terence J. Colgan Jennifer L. Hunt Time 8:30 AM Pre-analytic Variables in Molecular Testing Philip A. Branton 8:40 AM Carcinoma of Unknown Primary Site Is Gene Expression Profiling
More information